The FDA has approved Otsuka Pharmaceutical’s SIMTRIYO (centanafadine) for the treatment of attention...
January The FDA approves the esketamine nasal spray Spravato as a monotherapy for adults with treatm...
The FDA has approved Otsuka Pharmaceutical’s SIMTRIYO (centanafadine) for the treatment of attention...
January The FDA approves the esketamine nasal spray Spravato as a monotherapy for adults with treatm...